Anxiolytic Effects of a Semipurified Constituent of Guaraná Seeds on Rats in the Elevated T-Maze Test

Abstract

The objective of this study was to investigate the effects of chronic administration of a semi-purified extract (Purified Extract A – PEA; 4, 8, or 16 mg/kg) of Paullinia cupana (guaraná) seeds on rats submitted to the elevated T-maze (ETM) model of generalized anxiety and panic disorders. The selective serotonin (5-HT) reuptake inhibitor (SSRI) paroxetine (PAR; 3 mg/kg), was used as a positive control. To evaluate possible serotonergic and dopaminergic neurotransmission involvement in the action of PEA during the ETM test, ineffective doses of metergoline (MET; 5-HT_2A/2C antagonist receptor) or sulpiride (SUL; dopaminergic receptor antagonist) were acutely administered together with the PEA. The locomotion of the rats was assessed in a circular arena following each drug treatment. Both PEA (8 and 16 mg/kg) and PAR (3 mg/kg) increased one-way escape latencies from the open arm of the ETM, indicating a panicolytic effect compared to the control group. MET, in higher doses (1, 2 or 3 mg/kg), produced a panicolytic effect in the ETM test, whereas SUL did not (10, 20 or 40 mg/kg). The panicolytic effect produced by PEA (8 mg/kg) was blocked by both MET (2 mg/kg) and SUL (20 mg/kg), whereas the panicolytic effect produced by PAR (3 mg/kg) was blocked only by MET (2 mg/kg). These results show that chronic treatment with PEA produces a panicolytic effect during the ETM test, and that the dopaminergic and the serotonergic neurotransmission systems are involved in this effect.

Key words

elevated T maze - guaraná - HPLC - Paullinia cupana - Sapindaceae - panic disorder - serotonin

References

• 1 Kessler R C, Berglund P, Demler O, Jin R, Merikangas K R, Walters E E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national Comorbidity Survey Replication.  Arch Gen Psychiatry. 2005;  62 593-602
• 2 DuPont R L, Rice D P, Miller L S, Shiraki S S, Rowland C R, Harwood H J. Economic costs of anxiety disorders.  Anxiety. 1996;  2 167-172
• 3 Henderson M, Glozier N, Elliott K H. Long term sickness absence.  BMJ. 2005;  330 802-803
• 4 Waghorn G, Chant D, White P, Whiteford H. Disability, employment and work performance among persons with ICD-10 anxiety disorders.  Aust N Z J Psychiatry. 2005;  39 55-66
• 5 Mendlowicz M V, Stein M B. Quality of life in individuals with anxiety disorders.  Am J Psychiatry. 2000;  157 669-682
• 6 Blier P, de Montigny C. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders.  Neuropsychopharmacology. 1999;  21 91S-98S
• 7 Thase M E, Rush A J. Treatment-resistant depression. Bloom FE, Kupfer DJ Psychopharmacology. New York; Raven Press 1995: 1081-1097
• 8 Domenic A C, Edgar P N. Benzodiazepine treatment of anxiety or insomnia in substance abuse patients.  Am J Addict. 2000;  9 276-284
• 9 Eisenberg D M, Davis R B, Ettner S L, Appel S, Wilkey S, VanRompay M, Kessler R C. Trends in alternative medicine use in the United States 1990 − 1997.  JAMA. 1998;  280 1569-1575
• 10 Astin J A. Why patients use alternative medicine: results of a national study.  JAMA. 1998;  279 1548-1553
• 11 Guerra M P, Nodari R O. Biodiversidade: aspectos biológicos, geográficos, legais e éticos. Simões CMO, Sckenkel EP, Gosman G, Mello JCP, Mentz LA, Petrovick PR Farmacognosia: da planta ao medicamento. Porto Alegre/Florianópolis; UFRGS/UFSC 2001: 13-26
• 12 Henman A R. Guaraná (Paullinia cupana var. sorbilis): Ecological and social perspectives on an economic plant of the central Amazon basin.  J Ethnopharmacol. 1982;  6 311-338
• 13 Benowitz N L. Clinical pharmacology of caffeine.  Annu Rev Pharmacol. 1990;  41 277-288
• 14 O'Dea J A. Consumption of nutritional supplements among adolescents: usage and perceived benefits.  Health Educ Res. 2003;  18 98-107
• 15 Mattei R, Dias R F, Espínola E B. Guaraná (Paullinia cupana): toxic behavioral effects in laboratory animals and antioxidant activity in vitro.  J Ethnopharmacol. 1998;  60 111-116
• 16 Kennedy D O, Haskell C F, Wesnes K A, Scholey A B. Improved cognitive performance in human volunteers following administration of guarana (Paullinia cupana) extract: comparison and interaction with Panax ginseng.  Pharmacol Biochem Behav. 2004;  79 401-411
• 17 Otobone F J, Sanches A C, Nagae R, Martins J V C, Obici S, Mello J C P, Audi E A. Effect of crude extract and its semi-purified constituents from guaraná seeds [Paullinia cupana var. sorbilis (Mart.) Lucke] on cognitive performance in Morris water maze in rats.  Braz Arch Biol Technol. 2005;  48 723-728
• 18 Otobone F J, Sanches A C, Nagae R, Martins J V C, Sela V R, Mello J C P, Audi E A. Effect of lyophilized extracts from guaraná seeds [Paullinia cupana var. sorbilis (Mart.) Ducke] on behavioral profiles in rats.  Phytother Res. 2007;  21 531-535
• 19 Haskell C F, Kennedy D O, Wesnes K A, Milne A L, Scholey A B. A double-blind, placebo-controlled, multi-dose evaluation of the acute behavioural effects of guaraná in humans.  J Psychopharmacol. 2007;  21 65-70
• 20 Pelozo M I G, Cardoso M L C, Mello J C P. Spectrophotometric determination of tannins and caffeine in preparations from Paullinia cupana var. sorbilis.  Braz Arch Biol Technol. 2008;  51 447-451
• 21 Teixeira R C, Zangrossi Jr H, Graeff F G. Behavioral effects of acute and chronic imipramine in the elevated T-maze model of anxiety.  Pharmacol Biochem Behav. 2000;  65 571-576
• 22 El Mohsen M M A, Kuhnle G, Rechner A R, Schroeter H, Rose S, Jenner P, Rice-Evans C A. Uptake and metabolism of epicatechin and its access to the brain after oral ingestion.  Free Radic Biol Med. 2002;  33 1693-1702
• 23 Pietta P G. Flavonoids as antioxidants.  J Nat Prod. 2000;  63 1035-1042
• 24 Ying Y, Zang J T, Shi C Z, Liu Y. Study on the nootropic mechanism of ginsenoside Rb1 and Rb1-influene on mouse brain development.  Acta Pharm Sin. 1994;  29 241-245
• 25 Lee S C, Moon Y S, You K H. Effect of red ginseng saponins and nootropic drugs on impaired acquisition of ethanol-treated rats in passive avoidance performance.  J Ethnopharmacol. 2000;  69 1-8
• 26 Kim T, Pae C, Yoon S, Bahk W, Jun T, Rhee W, Chae J. Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder.  Psychiatry Clin Neurosci. 2006;  60 347-351
• 27 Pollack M H, Doyle A C. Treatment of panic disorder: Focus on paroxetine.  Psychopharmacol Bull. 2003;  37 53-63
• 28 Weber M, Talmon S, Schulze I, Boeddinghaus C, Gross G, Schoemaker H, Wicke K M. Running wheel activity is sensitive to acute treatment with selective inhibitors for either serotonin or norepinephrine reuptake.  Psychopharmacology. 2009;  203 753-762
• 29 Lepola U, Bergtholdt B, Lambert J S, Davy K L, Ruggiero L. Controlled-release paroxetine in the treatment of patients with social anxiety disorder.  J Clin Psychiatry. 2004;  65 222-229
• 30 Kim Y, Asukai N, Konishi T, Kato H, Hirotsune H, Maeda M, Inoue H, Narita H, Iwasaki M. Clinical evaluation of paroxetine in post-traumatic stress disorder (PTSD): 52-week, non-comparative open-label study for clinical use experience.  Psychiatry Clin Neurosci. 2008;  62 646-652
• 31 Trivedi M H, Pigott T A, Perera P, Dillingham K E, Carfagno M L, Pitts C D. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.  J Clin Psychiatry. 2004;  65 1356-1364
• 32 Antonelli-Ushirobira T M, Kaneshina E N, Gabriel M, Audi E A, Marques L C, Mello J C P. Acute and subchronic toxicological evaluation of the semipurified extract of seeds of guaraná (Paullinia cupana) in rodents.  Food Chem Toxicol. 2010;  48 1817-1820
• 33 Sheehan D V, Burnhan D B, Iyengar M K, Perera P. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder.  J Clin Psychiatry. 2005;  66 34-40
• 34 Simon N M, Emmanuel N, Ballenger J, Worthington J J, Kinrys G, Korbly N B, Farach F J, Pollack M H. Buproprion sustained release for panic disorder.  Psychopharmacol Bull. 2003;  37 66-72
• 35 Goodnick P J, Dominguez R A, DeVane C L, Bowden C L. Buproprion slow-release response in depression: diagnosis and biochemistry.  Biol Psychiatry. 1998;  44 629-632